Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension

Clinical Rheumatology

Volumn 27, Issue 8, 2008, Pages 955-960

  Stakkestad, Jacob A ^a   Lakatos, Peter ^b   Lorenc, Roman ^c   Sedarati, Farhad ^d   Neate, Colin ^e   Reginster, Jean Yves ^f  

^a CECOR AS   (Norway)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d HOFFMANN LA ROCHE INC   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bone mineral density; Bone turnover; Ibandronate; Monthly; Serum CTX

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE ALPHA CHAIN; IBANDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 47349114233     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0824-6     Document Type: Article

References (9)

1. Summary of Product Characteristics. Bonviva 150 mg Film-Coated Tablets (2007)
2. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236
3. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
4. Miller PD, McClung M, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315-1322
5. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661
6. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-38
7. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Schimmer R, Mahoney P, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
8. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: Results from the PERSIST study. Int J Clin Pract 60:896-905
9. Hadji P, Cziraky M, Harley C, Middelhoven H, Barr CE, Poston S, Cooper C (2007) Monthly ibandronate improves persistence vs weekly bisphosphonates after 9 months of treatment. Osteoporos Int 18(Suppl. 1):S141 Abstract P333